Trial Profile

Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NTLA-5001 (Primary) ; Cyclophosphamide; Fludarabine
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man
Sponsors Intellia Therapeutics

Most Recent Events

13 Oct 2022 Status changed from active, no longer recruiting to discontinued.
08 Aug 2022 Status changed from recruiting to active, no longer recruiting.
01 Mar 2022 According to Intellia Therapeutics media release, the first patient has been dosed with NTLA-5001

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com